At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RYTM Rhythm Pharmaceuticals Inc.
Post-Mkt 04-07 18:49:04 EDT
86.66
-0.30
-0.34%
盘后87.86
+1.20+1.38%
18:38 EDT
High86.99Low83.89Vol747.79K
Open86.82D1 Closing86.96Amplitude3.57%
Mkt Cap5.92BTradable Cap4.81BTotal Shares68.29M
T/O64.30MT/O Rate1.35%Tradable Shares55.48M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Why Rhythm Pharmaceuticals (RYTM) Is Up 12.6% After EU IMCIVREE Expansion Boost and Board Refresh – And What's Next
Simply Wall St.  ·  03:14
Why Rhythm Pharmaceuticals (RYTM) Is Up 12.6% After EU IMCIVREE Expansion Boost and Board Refresh – And What's Next
Rhythm Pharmaceuticals appoints Popovits to board of directors
TIPRANKS  ·  04-06 09:15
Rhythm Pharmaceuticals appoints Popovits to board of directors
A Look At Rhythm Pharmaceuticals (RYTM) Valuation After IMCIVREE Approval Expands Obesity Treatment Reach
Simply Wall St.  ·  04-04
A Look At Rhythm Pharmaceuticals (RYTM) Valuation After IMCIVREE Approval Expands Obesity Treatment Reach
Rhythm Pharmaceuticals appoints Kim Popovits to board as Ed Mathers exits
Reuters  ·  04-03
Rhythm Pharmaceuticals appoints Kim Popovits to board as Ed Mathers exits
Rhythm Pharmaceuticals Announces Changes to Board of Directors
THOMSON REUTERS  ·  04-03
Rhythm Pharmaceuticals Announces Changes to Board of Directors
Rhythm Pharmaceuticals (RYTM) Is Down 13.3% After EMA Backs IMCIVREE Label Expansion for Hypothalamic Obesity
Simply Wall St.  ·  03-30
Rhythm Pharmaceuticals (RYTM) Is Down 13.3% After EMA Backs IMCIVREE Label Expansion for Hypothalamic Obesity
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL) and Rhythm Pharmaceuticals (RYTM)
TIPRANKS  ·  03-27
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL) and Rhythm Pharmaceuticals (RYTM)
Rhythm Pharmaceuticals rises; CHMP recommends expanding IMCIVREE EU authorization for acquired hypothalamic obesity, EC decision due Q2 2026
Reuters  ·  03-26
Rhythm Pharmaceuticals rises; CHMP recommends expanding IMCIVREE EU authorization for acquired hypothalamic obesity, EC decision due Q2 2026
Rhythm Pharmaceuticals Inc: European Commission Decision Anticipated in Q2 of 2026
THOMSON REUTERS  ·  03-26
Rhythm Pharmaceuticals Inc: European Commission Decision Anticipated in Q2 of 2026
Rhythm Pharmaceuticals Receives Positive Chmp Opinion for Imcivree® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients With Acquired Hypothalamic Obesity Due to Hypothalamic Injury or Impairment
THOMSON REUTERS  ·  03-26
Rhythm Pharmaceuticals Receives Positive Chmp Opinion for Imcivree® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients With Acquired Hypothalamic Obesity Due to Hypothalamic Injury or Impairment
Rhythm Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  03-23
Rhythm Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Rhythm Pharmaceuticals price target raised to $105 from $100 at H.C. Wainwright
TIPRANKS  ·  03-23
Rhythm Pharmaceuticals price target raised to $105 from $100 at H.C. Wainwright
Assessing Rhythm Pharmaceuticals (RYTM) Valuation After FDA Approval Expands IMCIVREE’s Obesity Indication
Simply Wall St.  ·  03-23
Assessing Rhythm Pharmaceuticals (RYTM) Valuation After FDA Approval Expands IMCIVREE’s Obesity Indication
Rhythm Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $105 From $100
THOMSON REUTERS  ·  03-23
Rhythm Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $105 From $100
Rhythm Pharmaceuticals picks PANTHERx Rare as exclusive US pharmacy partner for IMCIVREE expanded indication
Reuters  ·  03-21
Rhythm Pharmaceuticals picks PANTHERx Rare as exclusive US pharmacy partner for IMCIVREE expanded indication
Rhythm Pharmaceuticals price target raised to $149 from $139 at BofA
TIPRANKS  ·  03-20
Rhythm Pharmaceuticals price target raised to $149 from $139 at BofA
Palatin’s Case Strengthens as Rhythm’s FDA Approval Validates Hypothalamic Obesity Market (PTN)
TIPRANKS  ·  03-20
Palatin’s Case Strengthens as Rhythm’s FDA Approval Validates Hypothalamic Obesity Market (PTN)
BUZZ-U.S. STOCKS ON THE MOVE-Unilever, Janus, Arm Holdings
Reuters  ·  03-20
BUZZ-U.S. STOCKS ON THE MOVE-Unilever, Janus, Arm Holdings
Rhythm Pharmaceuticals Is Maintained at Market Outperform by Citizens
Dow Jones  ·  03-20
Rhythm Pharmaceuticals Is Maintained at Market Outperform by Citizens
BUZZ-U.S. STOCKS ON THE MOVE-Unilever, Gemini Space Station, FedEx
Reuters  ·  03-20
BUZZ-U.S. STOCKS ON THE MOVE-Unilever, Gemini Space Station, FedEx

Introduction

Company Name.
Rhythm Pharmaceuticals Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Issue price:
--